Diagnosis and management of Duchenne muscular dystrophy, part 2 : respiratory, cardiac, bone health, and orthopaedic management
Copyright © 2018 Elsevier Ltd. All rights reserved..
A coordinated, multidisciplinary approach to care is essential for optimum management of the primary manifestations and secondary complications of Duchenne muscular dystrophy (DMD). Contemporary care has been shaped by the availability of more sensitive diagnostic techniques and the earlier use of therapeutic interventions, which have the potential to improve patients' duration and quality of life. In part 2 of this update of the DMD care considerations, we present the latest recommendations for respiratory, cardiac, bone health and osteoporosis, and orthopaedic and surgical management for boys and men with DMD. Additionally, we provide guidance on cardiac management for female carriers of a disease-causing mutation. The new care considerations acknowledge the effects of long-term glucocorticoid use on the natural history of DMD, and the need for care guidance across the lifespan as patients live longer. The management of DMD looks set to change substantially as new genetic and molecular therapies become available.
| Errataetall: |
CommentIn: Lancet Neurol. 2018 May;17(5):389-391. - PMID 29656735 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
The Lancet. Neurology - 17(2018), 4 vom: 15. Apr., Seite 347-361 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Birnkrant, David J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 27.02.2019 Date Revised 08.04.2022 published: Print-Electronic CommentIn: Lancet Neurol. 2018 May;17(5):389-391. - PMID 29656735 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1474-4422(18)30025-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM280559011 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM280559011 | ||
| 003 | DE-627 | ||
| 005 | 20231225025610.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1474-4422(18)30025-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0935.xml |
| 035 | |a (DE-627)NLM280559011 | ||
| 035 | |a (NLM)29395990 | ||
| 035 | |a (PII)S1474-4422(18)30025-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Birnkrant, David J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and management of Duchenne muscular dystrophy, part 2 |b respiratory, cardiac, bone health, and orthopaedic management |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2019 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Lancet Neurol. 2018 May;17(5):389-391. - PMID 29656735 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier Ltd. All rights reserved. | ||
| 520 | |a A coordinated, multidisciplinary approach to care is essential for optimum management of the primary manifestations and secondary complications of Duchenne muscular dystrophy (DMD). Contemporary care has been shaped by the availability of more sensitive diagnostic techniques and the earlier use of therapeutic interventions, which have the potential to improve patients' duration and quality of life. In part 2 of this update of the DMD care considerations, we present the latest recommendations for respiratory, cardiac, bone health and osteoporosis, and orthopaedic and surgical management for boys and men with DMD. Additionally, we provide guidance on cardiac management for female carriers of a disease-causing mutation. The new care considerations acknowledge the effects of long-term glucocorticoid use on the natural history of DMD, and the need for care guidance across the lifespan as patients live longer. The management of DMD looks set to change substantially as new genetic and molecular therapies become available | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Bushby, Katharine |e verfasserin |4 aut | |
| 700 | 1 | |a Bann, Carla M |e verfasserin |4 aut | |
| 700 | 1 | |a Alman, Benjamin A |e verfasserin |4 aut | |
| 700 | 1 | |a Apkon, Susan D |e verfasserin |4 aut | |
| 700 | 1 | |a Blackwell, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Case, Laura E |e verfasserin |4 aut | |
| 700 | 1 | |a Cripe, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjiyannakis, Stasia |e verfasserin |4 aut | |
| 700 | 1 | |a Olson, Aaron K |e verfasserin |4 aut | |
| 700 | 1 | |a Sheehan, Daniel W |e verfasserin |4 aut | |
| 700 | 1 | |a Bolen, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Leanne M |e verfasserin |4 aut | |
| 700 | 0 | |a DMD Care Considerations Working Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Neurology |d 2002 |g 17(2018), 4 vom: 15. Apr., Seite 347-361 |w (DE-627)NLM126098468 |x 1474-4465 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2018 |g number:4 |g day:15 |g month:04 |g pages:347-361 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1474-4422(18)30025-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2018 |e 4 |b 15 |c 04 |h 347-361 | ||